While providers and care systems can agree that effective patient navigation programs are essential to positive patient outcomes, there have been no standard metrics that could be used to measure the success of navigation programs and establish benchmarks for improvement.
Creating Value in Cancer Care Through Standardized Metrics and Partnerships Between Patient Navigators and Physicians
As most cancer patients are seen in the community setting, community oncologists will play an instrumental role in patient referral and likely determine the initial adoption of CAR-T therapies.
The promise of CAR-T therapies as a potential cure for cancers and the pressure that this creates in the market will likely serve to highlight the ineffective areas in our health care system, as providers contend with multiple barriers associated with the therapy.
Researchers identified critical educational gaps that need to be addressed by manufacturers and policymakers in order for biosimilars to achieve their potential for lowering the cost of cancer care in the United States.
The simulation provided an opportunity for meeting attendees to observe the process by which oncologists determine initial diagnostic tests critical to treatment selection, the most appropriate treatment for each line of therapy, and criteria for subsequent treatment selection.
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
Systemic therapy for bladder cancer is costly and should be weighed against the clinical outcomes likely to be achieved.
Through an appreciation of heuristics, we can better understand the factors that influence the decision-making processes of different stakeholders and adjust our approach to delivering value-based care to our patients.
This retrospective, longitudinal study was conducted to identify drivers of chronic kidney disease stage progression and associated health care costs.
Express Scripts recently announced the purchase of eviCore, a leading medical benefits management firm, for $3.6 billion. The merger has the potential to be the first comprehensive care management offering.